Mittie Doyle

CIK: 0001918845

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)17 (41.5%)

Position reduction

Option Exercises (M)17 (41.5%)

Derivative conversions

Awards (A)5 (12.2%)

Compensation grants

Other (G, F, J, C, D, …)2 (4.9%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

AVTX

Avalo Therapeutics, Inc.

Officer

CGEM

Cullinan Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (41 total)

AVTX
Avalo Therapeutics, Inc.
Aug 28, 2026
Exercise(M)
Direct
679 shares at avg. $8.04$5K
AVTX
Avalo Therapeutics, Inc.
Aug 28, 2026
Sale(S)
Direct
679 shares at avg. $20.00$14K
AVTX
Avalo Therapeutics, Inc.
Aug 17, 2026
Sale(S)
Direct
1K shares at avg. $20.00$20K
AVTX
Avalo Therapeutics, Inc.
Aug 17, 2026
Exercise(M)
Direct
1K shares at avg. $12.65$13K
AVTX
Avalo Therapeutics, Inc.
Aug 10, 2026
Sale(S)
Direct
679 shares at avg. $20.00$14K
AVTX
Avalo Therapeutics, Inc.
Aug 10, 2026
Exercise(M)
Direct
679 shares at avg. $8.04$5K
AVTX
Avalo Therapeutics, Inc.
Jul 27, 2026
Exercise(M)
Direct
1K shares at avg. $12.65$13K
AVTX
Avalo Therapeutics, Inc.
Jul 27, 2026
Sale(S)
Direct
1K shares at avg. $20.00$20K
AVTX
Avalo Therapeutics, Inc.
Jun 30, 2026
Exercise(M)
Direct
2.9K shares at avg. $12.65$36K
AVTX
Avalo Therapeutics, Inc.
Jun 30, 2026
Sale(S)
Direct
4.7K shares at avg. $20.00$93K
AVTX
Avalo Therapeutics, Inc.
Jun 30, 2026
Exercise(M)
Direct
1.8K shares at avg. $8.04$14K
AVTX
Avalo Therapeutics, Inc.
Jun 23, 2026
Exercise(M)
Direct
1.5K shares at avg. $8.04$12K
AVTX
Avalo Therapeutics, Inc.
Jun 23, 2026
Sale(S)
Direct
1.5K shares at avg. $18.00$26K
CGEM
Cullinan Therapeutics, Inc.
Jun 16, 2026
Award(A)
Stock Option (Right to Buy)
Direct
21.8K shares-
AVTX
Avalo Therapeutics, Inc.
Jun 10, 2026
Tax Payment(F)
Direct
1.1K shares at avg. $13.10$14K
AVTX
Avalo Therapeutics, Inc.
May 28, 2026
Exercise(M)
Direct
679 shares at avg. $8.04$5K
AVTX
Avalo Therapeutics, Inc.
May 28, 2026
Sale(S)
Direct
679 shares at avg. $16.00$11K
AVTX
Avalo Therapeutics, Inc.
May 21, 2026
Award(A)
Direct
43.5K shares-
AVTX
Avalo Therapeutics, Inc.
May 15, 2026
Exercise(M)
Direct
3K shares at avg. $12.65$38K
AVTX
Avalo Therapeutics, Inc.
May 15, 2026
Sale(S)
Direct
3K shares at avg. $18.76$56K
AVTX
Avalo Therapeutics, Inc.
May 6, 2026
Sale(S)
Direct
10.1K shares at avg. $22.88$230K
AVTX
Avalo Therapeutics, Inc.
May 6, 2026
Exercise(M)
Direct
77.9K shares at avg. $12.65$985K
AVTX
Avalo Therapeutics, Inc.
May 6, 2026
Exercise(M)
Direct
28.7K shares at avg. $8.04$230K
AVTX
Avalo Therapeutics, Inc.
May 6, 2026
Sale(S)
Direct
27.5K shares at avg. $18.03$496K
AVTX
Avalo Therapeutics, Inc.
May 6, 2026
Sale(S)
Direct
5K shares at avg. $19.65$98K

		Type	Shares	Price		Ownership
Aug 28, 2026	AVTX Avalo Therapeutics, Inc.	Exercise(M)	679	$8.04	$5,459	Direct
Aug 28, 2026	AVTX Avalo Therapeutics, Inc.	Sale(S)	679	$20.00	$13,580	Direct
Aug 17, 2026	AVTX Avalo Therapeutics, Inc.	Sale(S)	1,000	$20.00	$20,000	Direct
Aug 17, 2026	AVTX Avalo Therapeutics, Inc.	Exercise(M)	1,000	$12.65	$12,650	Direct
Aug 10, 2026	AVTX Avalo Therapeutics, Inc.	Sale(S)	679	$20.00	$13,580	Direct
Aug 10, 2026	AVTX Avalo Therapeutics, Inc.	Exercise(M)	679	$8.04	$5,459	Direct
Jul 27, 2026	AVTX Avalo Therapeutics, Inc.	Exercise(M)	1,000	$12.65	$12,650	Direct
Jul 27, 2026	AVTX Avalo Therapeutics, Inc.	Sale(S)	1,000	$20.00	$20,000	Direct
Jun 30, 2026	AVTX Avalo Therapeutics, Inc.	Exercise(M)	2,875	$12.65	$36,369	Direct
Jun 30, 2026	AVTX Avalo Therapeutics, Inc.	Sale(S)	4,654	$20.00	$93,080	Direct
Jun 30, 2026	AVTX Avalo Therapeutics, Inc.	Exercise(M)	1,779	$8.04	$14,303	Direct
Jun 23, 2026	AVTX Avalo Therapeutics, Inc.	Exercise(M)	1,450	$8.04	$11,658	Direct
Jun 23, 2026	AVTX Avalo Therapeutics, Inc.	Sale(S)	1,450	$18.00	$26,100	Direct
Jun 16, 2026	CGEM Cullinan Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	21,781	-	-	Direct
Jun 10, 2026	AVTX Avalo Therapeutics, Inc.	Tax Payment(F)	1,084	$13.10	$14,200	Direct
May 28, 2026	AVTX Avalo Therapeutics, Inc.	Exercise(M)	679	$8.04	$5,459	Direct
May 28, 2026	AVTX Avalo Therapeutics, Inc.	Sale(S)	679	$16.00	$10,864	Direct
May 21, 2026	AVTX Avalo Therapeutics, Inc.	Award(A)	43,500	-	$0	Direct
May 15, 2026	AVTX Avalo Therapeutics, Inc.	Exercise(M)	3,000	$12.65	$37,950	Direct
May 15, 2026	AVTX Avalo Therapeutics, Inc.	Sale(S)	3,000	$18.76	$56,280	Direct
May 6, 2026	AVTX Avalo Therapeutics, Inc.	Sale(S)	10,058	$22.88	$230,127	Direct
May 6, 2026	AVTX Avalo Therapeutics, Inc.	Exercise(M)	77,905	$12.65	$985,498	Direct
May 6, 2026	AVTX Avalo Therapeutics, Inc.	Exercise(M)	28,650	$8.04	$230,346	Direct
May 6, 2026	AVTX Avalo Therapeutics, Inc.	Sale(S)	27,538	$18.03	$496,405	Direct
May 6, 2026	AVTX Avalo Therapeutics, Inc.	Sale(S)	5,000	$19.65	$98,251	Direct

1-25 of 41 transactions

About Doyle Mittie

Doyle Mittie (SEC CIK 0001918845) files insider reports with the SEC as Chief Medical Officer of Avalo Therapeutics, Inc. (AVTX) and Director of Cullinan Therapeutics, Inc. (CGEM).

Signal8 holds 20 ownership filings by Doyle Mittie (1 Form 3, 19 Form 4), filed between Jan 30, 2025 and Sep 1, 2026. Those filings report 41 transactions, from Jan 28, 2025 to Aug 28, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Doyle Mittie's filings is in WAYNE, PA.

Recent filings by Doyle Mittie

Aug 28, 2026: Option exercise of AVTX shares (Form 4, code M).
Aug 28, 2026: Open-market sale of AVTX shares (Form 4, code S).
Aug 17, 2026: Open-market sale of AVTX shares (Form 4, code S).
Aug 17, 2026: Option exercise of AVTX shares (Form 4, code M).
Aug 10, 2026: Open-market sale of AVTX shares (Form 4, code S).

Other insiders filing for Avalo Therapeutics, Inc. (AVTX)

Jain Rita, Director
Lind Kevin Robert, Director
Philip Ron M, Director
Sullivan Christopher Ryan, Chief Financial Officer
Riley Jennifer, Chief Strategy Officer
VARKI PAUL, Chief Legal Officer

How to read Form 4 transaction codes